BDX Q3 FY2026: revenue up 5.4%, adjusted EPS beat, guidance midpoint raised
BD's fiscal third quarter was a beat-and-raise: adjusted EPS of $3.23 topped the $3.17 consensus, revenue rose 5.4% to $4.98 billion, and management lifted the midpoint of full-year adjusted EPS guidance. Gross margin slipped to 46.5% and GAAP net income fell 34.3% to $377 million on a discontinued-operations loss, so read the adjusted headline next to the GAAP one.
1 · Expected vs. Actual
Free preview belowAdjusted diluted EPS from continuing operations was $3.23, up 4.9% and ahead of the $3.17 consensus, while GAAP EPS from continuing operations was $1.64. The gap is mostly purchase accounting: $1.32 of the adjusted $3.23 comes from excluding amortization and similar items. Reported diluted EPS including discontinued operations was $1.37, down 31.5%, because the quarter carried a $0.27 per-share loss from the spun-off business versus a $0.43 gain a year earlier.
Revenue was $4.98 billion, up 5.4% as reported and 4.4% in constant currency, with the U.S. up 6.9% and international up just 0.6% after currency drag. Growth was broad: Interventional and BioPharma Systems rose 6.4% and 6.6%, ahead of the group, while Medical Essentials grew 4.5% and Connected Care 4.9%. Every segment contributed, but the quarter's momentum leaned on the U.S. and on the two smaller units.
Log in to read 5 analyses a week for free
Create a free account to read 5 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.